Genomic Cancer Panel And Profiling Market Report 2026

Genomic Cancer Panel And Profiling Market Overview

• Genomic Cancer Panel And Profiling market size has reached to $10.28 billion in 2025 • Expected to grow to $15.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Rising Cancer Incidence Driving The Growth Of The Market Due To Aging Population And Improved Detection • Market Trend: Enhancing Diagnostic Accuracy Through Technological Integration • North America was the largest region in 2025.

The key promising market opportunities in the genomic cancer panel and profiling market include: • Solid Tissue Testing (Segmentation By Tissue Testing) → Expected gain of $3.52 Billion • Liquid Tissue Testing (Segmentation By Tissue Testing) → Expected gain of $1.83 Billion

What Is Covered Under Genomic Cancer Panel And Profiling Market?

Genomic cancer panel and profiling is a molecular diagnostic technique that analyzes multiple genes simultaneously to detect genetic mutations, alterations, or biomarkers associated with cancer. Its primary purpose is to guide personalized treatment decisions, predict disease progression, and improve cancer diagnosis and monitoring. The main tissue testing types in the genomic cancer panel and profiling market are solid tissue testing and liquid tissue testing. Solid tissue testing is a diagnostic procedure that analyzes samples from solid tumors or organs to identify genetic mutations, biomarkers, or disease characteristics. Various technologies are used in this process, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others, with cancer panels including single-gene panels and multi-gene panels. These tests are used in a variety of applications, including clinical and research settings, by end users such as hospitals, research and academic institutes, clinical and diagnostic laboratories, and other end users.

What Is The Genomic Cancer Panel And Profiling Market Growth Forecast?

The genomic cancer panel and profiling market size is expected to see strong growth in the next few years. It will grow to $15.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to expansion of companion diagnostics, growth in liquid biopsy adoption, integration of ai in genomic analysis, increasing oncology screening programs, development of cost-effective sequencing platforms. Major trends in the forecast period include increasing adoption of multi-gene cancer panels, rising use of next-generation sequencing, expansion of liquid biopsy testing, growing demand for personalized oncology, integration of genomic data in clinical decision-making.

What Is The Driver Of The Genomic Cancer Panel And Profiling Market?

Rising cancer incidence is expected to propel the growth of the genomic cancer panel and profiling market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer incidence is due to an aging population, which increases the likelihood of developing cancer as life expectancy continues to grow. Genomic cancer panels and profiling support oncology care by identifying genetic mutations and biomarkers, enabling personalized treatment strategies, and improving early detection and monitoring.For instance, in January 2024, according to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, around 20 million new cancer cases were reported globally, resulting in 9.7 million deaths; driven primarily by population growth, the global cancer burden is projected to rise to 35 million cases by 2050. Therefore, rising cancer incidence will drive the growth of the genomic cancer panel and profiling industry.

How Will The Drivers Impact Growth In The Global Genomic Cancer Panel And Profiling Market?

• Rising Adoption Of Precision Oncology (High) – During the forecast period, the rising adoption of precision oncology is expected to become a key growth driver for the genomic cancer panel and profiling market by 2030. Healthcare providers are increasingly leveraging genomic insights to tailor treatment strategies based on individual patient mutations and tumor profiles. This shift toward targeted therapies is enhancing clinical outcomes and minimizing ineffective treatments. Advanced sequencing technologies are enabling comprehensive genomic analysis, supporting oncologists in selecting optimized therapeutic regimens. As precision oncology becomes central to cancer care, demand for genomic profiling solutions continues to expand. • Growing Incidence Of Cancer Globally (High) – During the forecast period, the growing incidence of cancer globally is expected to emerge as a major factor driving the expansion of the genomic cancer panel and profiling market by 2030. Increasing cancer prevalence is creating a higher demand for early detection, accurate diagnosis, and continuous disease monitoring solutions. Healthcare systems are prioritizing scalable diagnostic technologies to manage the rising patient burden effectively. Genomic profiling enables identification of cancer subtypes and progression patterns, supporting timely clinical intervention. With cancer cases continuing to rise worldwide, the need for advanced genomic testing is expanding significantly. • Increasing Use Of Companion Diagnostics (Medium) – During the forecast period, the increasing use of companion diagnostics is expected to act as a key growth catalyst for the genomic cancer panel and profiling market by 2030. Pharmaceutical companies are increasingly co-developing targeted therapies alongside diagnostic tests to identify suitable patient populations. This alignment between therapeutics and diagnostics is improving treatment efficacy and accelerating drug approval processes. Regulatory support for biomarker-based therapies is further strengthening the role of genomic profiling in clinical decision-making. As targeted drug pipelines expand, the integration of companion diagnostics is expected to rise steadily.

How Will The Restraints Impact Growth In The Global Genomic Cancer Panel And Profiling Market?

• High Cost Of Genomic Testing And Instruments (High) – During the forecast period, high cost of genomic testing and instruments is restricting the growth of the genomic cancer panel and profiling market. Expensive sequencing technologies, advanced laboratory equipment, and high operational costs are increasing financial burden on healthcare providers and patients, thereby limiting widespread adoption • Limited Reimbursement Coverage In Several Regions (High) – During the forecast period, limited reimbursement coverage in several regions is restricting the growth of the genomic cancer panel and profiling market. Inadequate insurance support and inconsistent reimbursement policies are reducing accessibility to advanced genomic testing services, particularly in developing markets • Complexity In Data Interpretation And Shortage Of Skilled Professionals (Medium) – During the forecast period, complexity in data interpretation and shortage of skilled professionals is restricting the growth of the genomic cancer panel and profiling market. Challenges in analyzing complex genomic data along with limited availability of trained bioinformaticians and genetic specialists are hindering effective clinical implementation

Key Players In The Global Genomic Cancer Panel And Profiling Market

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Global Genomic Cancer Panel And Profiling Market Trends and Insights

Major companies operating in the genomic cancer panel and profiling market are focusing on technological advancements such as next-generation sequencers to improve the accuracy, speed, and comprehensiveness of cancer diagnostics and enable more personalized treatment decisions. Next-generation sequencers are advanced DNA sequencing technologies that enable rapid, high-throughput analysis of genetic material to identify mutations, variations, and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels designed for next-generation sequencers, enabling comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, aiming to improve cancer diagnostics and treatment strategies.

What Are Latest Mergers And Acquisitions In The Genomic Cancer Panel And Profiling Market?

In June 2023, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology for an undisclosed amount. Through its acquisition, Quest Diagnostics expanded its capabilities in liquid biopsy and cancer detection, enhancing its genomic testing offerings. Haystack Oncology is a US-based biotech company focused on developing innovative liquid biopsy technologies for early cancer detection and monitoring.

What Defines the Genomic Cancer Panel And Profiling Market?

The genomic cancer panel and profiling market consists of revenues earned by entities by providing services such as genetic mutation analysis, companion diagnostic testing, cancer risk assessment, and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic cancer panel and profiling market also includes sales of targeted gene panels, companion diagnostic kits, sequencing platforms and instruments, bioinformatics software, and analysis tools. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genomic Cancer Panel And Profiling Market Report 2026?

The genomic cancer panel and profiling market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genomic cancer panel and profiling industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.